Wall Street Analysts See 93.31% for Heat Biologics Inc. (HTBX)

Publicly-traded company Heat Biologics Inc. (NASDAQ:HTBX) had a closing price of $0.46 yesterday. Meanwhile, the average 12-month price target from Wall Street analysts is currently $6.88, this means that the stock is underpriced by 93.31%. In the past 52 weeks the company’s stock price has moved within the range of $0.35 to $2.10.

This particular stock’s 5-day moving average is 0.53, its 20-day moving average is 0.44 and its 100-day moving average is 0.56. Heat Biologics Inc. (HTBX) currently has 33.26M shares outstanding, which means that its market capitalization is $15.31M.

The Details: Heat Biologics Inc. (HTBX) Financial Health

Return on Assets, which is expressed as a percentage, tells us how well a public company is using its assets to turn a profit. The larger the percentage, the better it is At the moment, Heat Biologics Inc. Return on Assets is -57.10%.

What Does Wall Street Say about Company?

When selecting potential stocks to buy, many investors want to find out what Wall Street professionals are thinking about the company beforehand – like what the average analyst rating is. At the moment, the average analyst rating for HTBX is Buy. Out of 2 total analysts who were surveyed, 0 rated it a sell, 0 rated it a underweight, 0 rated it an overweight, 0 rated it hold, and 2 rated it a Buy.

Understanding Profitability at Heat Biologics Inc. (HTBX)

A good way of assessing a public company’s profitability is by looking at its Earnings per Share (EPS). In the most recent financial results released by Heat Biologics Inc., for the quarter ending on 09/2019, the company posted EPS of -0.16. The average estimate of Wall Street analysts had projected -0.14.

Wall Street analysts, on average, are forecasting the company’s EPS to be -0.15, compared to -0.16 reported in the same quarter last year.